ABSTRACT
BACKGROUND The aim of this study was to evaluate the psychological status of anxiety and depression of hospital staff in the designated hospital in the city of Shannan during the COVID-19 pandemic in order to provide a theoretical basis for effective psychological intervention. MATERIAL AND METHODS A cross-sectional survey was performed from September 10 to 16, 2022, by administering an online questionnaire to the hospital staff on duty in the hospital. We collected participants' demographic and general information. The Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS) were used to investigate the anxiety and depression of hospital staff. RESULTS Among 267 hospital staff, anxiety was found in 98 individuals, with a prevalence of 36.70%. Depression was found in 170 individuals, with a prevalence of 63.67%. Anxiety combined with depression was found in 84 individuals, with a prevalence of 31.46%. The prevalence of depression was higher in women, Tibetan personnel, hospital staff with primary or lower titles, staff without career establishment, and non-aid Tibetan personnel, and the differences were all statistically significant (P.
Subject(s)
COVID-19 , Humans , Female , COVID-19/epidemiology , Cross-Sectional Studies , Pandemics , SARS-CoV-2 , Anxiety/epidemiology , Personnel, Hospital/psychology , Surveys and Questionnaires , HospitalsABSTRACT
The lungs play a very important role in the human respiratory system. However, many factors can destroy the structure of the lung, causing several lung diseases and, often, serious damage to people's health. Nerve growth factor (NGF) is a polypeptide which is widely expressed in lung tissues. Under different microenvironments, NGF participates in the occurrence and development of lung diseases by changing protein expression levels and mediating cell function. In this review, we summarize the functions of NGF as well as some potential underlying mechanisms in pulmonary fibrosis (PF), coronavirus disease 2019 (COVID-19), pulmonary hypertension (PH), asthma, chronic obstructive pulmonary disease (COPD), and lung cancer. Furthermore, we highlight that anti-NGF may be used in future therapeutic strategies.